[Liebert] Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial

Closed

and618and Post time 2022-6-20 21:29:44 | Show all posts |Read mode

Reward10points

journal：Thyroid

Authors：Vatche Tchekmedyian; Lara Dunn; Eric Sherman; Shrujal S. Baxi; Ravinder K. Grewal; Steven M. Larson; Keith S. Pentlow; Sofia Haque; R. Michael Tuttle; Mona M. Sabra; Stephanie Fish; Laura Boucai; Jamie Walters; Ronald A. Ghossein; Venkatraman E. Seshan; Jeffrey A. Knauf; David G. Pfister; James A. Fagin; Alan L. Ho

Published date：2022-3-1

DOI：10.1089/thy.2021.0565

Article link：http://dx.doi.org/10.1089/thy.2021.0565

Article Source：Mary Ann Liebert Inc。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

and618and Lv.4

Senior Member

post
reply
points
800

[Liebert] Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Liebert] Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial Copy

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Liebert] Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial